FDA Circular No.2020-037-A || Extension of the Effectivity of FDA Circular No. 2020-037 Entitled “Reissuance of the Guidelines on the Implementation of the Use of Electronic Means Of Prescription for Drugs for the Benefit of Individuals Vulnerable to Covid-19

In the interest of service and due to the continuing COVID-19 Pandemic, the effectivity of FDA Circular No. 2020-037 entitled “Reissuance of the Guidelines on the Implementation of the Use of Electronic Means of Prescription for Drugs for the Benefit of Individuals Vulnerable to COVID-19” is hereby extended until 31 December 2021, regardless of the level of the imposed quarantine restrictions due to COVID-19.

For the information and guidance of the public.